Author details

Full Name

Paola Cavalla

Affiliation

ORCID

Career Start Year

1991

Papers

131

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37515480	May Mediterranean diet contribute to reduce risk of multiple sclerosis?		2023
37922069	SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose.		2023
37740714	Association of MRI leptomeningeal enhancement with disability worsening in progressive multiple sclerosis: A clinical and post-mortem study.		2023
37610702	Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY).		2023
37405689	Effectiveness of teriflunomide on No Evidence of Disease Activity and cognition in relapsing remitting multiple sclerosis: results of the NEDA3PLUS study.		2023
37454568	Quality of care provided by Multiple Sclerosis Centers during Covid-19 pandemic: Results of an Italian multicenter patient-centered survey.		2023
37058763	SARS-CoV-2 pandemic as a model to assess the relationship between intercurrent viral infections and disease activity in Multiple Sclerosis: A propensity score matched case-control study.		2023
36996621	Previous disease-modifying treatments influence T lymphocyte kinetics in people with multiple sclerosis switching to ocrelizumab.		2023
37232279	Sars-CoV2 infection in pregnant women with multiple sclerosis.		2023
37165941	Symptomatic COVID-19 course and outcomes after three mRNA vaccine doses in multiple sclerosis patients treated with high-efficacy DMTs.		2023
35305426	Lymphopenia in Multiple Sclerosis patients treated with Ocrelizumab is associated with an effect on CD8 T cells.	Multiple Sclerosis and Related Disorders	2022
35899485	Onset of multiple sclerosis in a patient on dupilumab therapy for atopic dermatitis: A case report.	Dermatologic Therapy	2022
36288659	The impact of PM2.5, PM10 and NO2 on Covid-19 severity in a sample of patients with multiple sclerosis: A case-control study.	Multiple Sclerosis and Related Disorders	2022
36086905	Signs and symptoms of COVID-19 in patients with multiple sclerosis.	European Journal of Neurology	2022
35377015	Correction to: Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study.	Journal of Neurology	2022
35625604	Inter-Laboratory Concordance of Cerebrospinal Fluid and Serum Kappa Free Light Chain Measurements.	Biomolecules	2022
35933740	Fetal and post-natal growth in infants of mothers with multiple sclerosis: A case-control stud.	Multiple Sclerosis and Related Disorders	2022
35735030	Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies.	Multiple Sclerosis Journal	2022
35675744	A multiparametric score for assessing the individual risk of severe Covid-19 among patients with Multiple Sclerosis.	Multiple Sclerosis and Related Disorders	2022
35672479	Do patients' and referral centers' characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register.	Neurol Sci	2022
36544324	Association of vitamin D serum levels and vitamin D supplementation with B cell kinetics and disease activity in Multiple Sclerosis patients treated with ocrelizumab: an Italian multi-center study.		2022
34124960	Acute and chronic synaptic pathology in multiple sclerosis gray matter.	Multiple Sclerosis Journal	2022
33454397	Prevalence and patterns of subclinical motor and cognitive impairments in non-disabled individuals with early multiple sclerosis: A multicenter cross-sectional study.	Annals of Physical and Rehabilitation Medicine	2022
34408003	mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis.	Journal of Neurology, Neurosurgery and Psychiatry	2022
35046084	Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.	Neurology: Neuroimmunology and NeuroInflammation	2022
35296189	Natalizumab treatment and pregnancy in multiple sclerosis: A reappraisal of maternal and infant outcomes after 6â¿¿years.	Multiple Sclerosis Journal	2022
34735749	The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis.	European Journal of Neurology	2022
34558755	A real-world study of alemtuzumab in a cohort of Italian patients.	European Journal of Neurology	2022
35150168	Comparing Natural History of Early and Late Onset Pediatric Multiple Sclerosis.	Annals of Neurology	2022
35166977	Dietary habits, nutritional status and risk of a first demyelinating event: an incident case-control study in a southern European cohort.	Neurological Sciences	2022
35165767	Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study.	Journal of Neurology	2022
35075574	Impact of COVID-19 lockdown on progressive multiple sclerosis patients.	Neurological Sciences	2022
34360456	CD19 Cell Count at Baseline Predicts B Cell Repopulation at 6 and 12 Months in Multiple Sclerosis Patients Treated with Ocrelizumab.	International Journal of Environmental Research and Public Health	2021
33691323	Validation of an Algorithm to Detect Multiple Sclerosis Cases in Administrative Health Databases in Piedmont (Italy): An Application to the Estimate of Prevalence by Age and Urbanization Level.	Neuroepidemiology	2021
33838554	A multicenter survey on access to care in Multiple Sclerosis-related trigeminal neuralgia.	Journal of the Neurological Sciences	2021
33616742	Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study.	J Neurol	2021
33770708	MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study.	Journal of the Neurological Sciences	2021
33506301	Paraneoplastic neuromyelitis optica spectrum disorders: a case series.	Neurological Sciences	2021
33305459	Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study.	European Journal of Neurology	2021
34744958	Case Report: Covid-19 in Multiple Sclerosis Patients Treated With Ocrelizumab: A Case Series.	Frontiers in Neurology	2021
31452081	Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?		2020
31837636	Kappa free light chains index in the differential diagnosis of Multiple Sclerosis from Neuromyelitis optica spectrum disorders and other immune-mediated central nervous system disorders.	Journal of Neuroimmunology	2020
31678859	Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: An Italian multi-centre study.	Multiple Sclerosis and Related Disorders	2020
31573386	Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience.	Multiple Sclerosis Journal	2020
32335779	Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study.	Neurological Sciences	2020
32655689	Sex effects across the lifespan in women with multiple sclerosis.	Ther Adv Neurol Disord	2020
33147889	Inhibition of Human Neutrophil Functions In Vitro by Multiple Sclerosis Disease-Modifying Therapies.	Journal of Clinical Medicine	2020
32683308	Harmonization of real-world studies in multiple sclerosis: Retrospective analysis from the rirems group.	Multiple Sclerosis and Related Disorders	2020
32661083	Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre study.	Journal of Neurology, Neurosurgery and Psychiatry	2020
30070597	Predicting the profile of increasing disability in multiple sclerosis.	Multiple Sclerosis Journal	2019